Results 41 to 50 of about 841,367 (303)

The zebrafish model tackles anti-P2Y

Blood Advances
: Antiplatelet drugs are a pillar in the treatment strategy to prevent ischemic events in patients with cardiovascular disease. However, the action of existing therapies is nonuniform, and the causative mechanism for this variability remains poorly ...
Paulina Ciepla, Richard J. Fish, Séverine Nolli, Sylvie Dunoyer-Geindre, Julia Charlon-Gay, Jean-Luc Reny, Marguerite Neerman-Arbez, Pierre Fontana   +7 more
doaj   +1 more source

Activated NK cells cause placental dysfunction and miscarriages in fetal alloimmune thrombocytopenia

Nature Communications, 2017
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a gestational disease caused by maternal immune responses against fetal platelets. Using a FNAIT mouse model and human trophoblast cell lines, here the authors show that uterine natural killer cell ...
Issaka Yougbaré, Wei-She Tai, Darko Zdravic, Brigitta Elaine Oswald, Sean Lang, Guangheng Zhu, Howard Leong-Poi, Dawei Qu, Lisa Yu, Caroline Dunk, Jianhong Zhang, John G. Sled, Stephen J. Lye, Jelena Brkić, Chun Peng, Petter Höglund, B. Anne Croy, S. Lee Adamson, Xiao-Yan Wen, Duncan J. Stewart, John Freedman, Heyu Ni   +21 more
doaj   +1 more source

Restrained glycoprotein VI-induced platelet signaling by tyrosine protein phosphatases independent of phospholipase Cγ2

Bleeding, Thrombosis and Vascular Biology, 2023
The platelet collagen receptor glycoprotein VI (GPVI) signals to activation of phospholipase Cγ2 (PLCγ2) and phosphoinositide 3-kinases (PI3K), causing platelet activation and aggregation.
Jingnan Huang, Delia I. Fernández, Jinmi Zou, Xueqing Wang, Johan W.M. Heemskerk, Ángel García   +5 more
doaj   +1 more source

Laboratory analyses for evaluation of platelet disorders and platelet concentrates [PDF]

, 2006
High quality of platelet analytics requires specialized knowledge and skills. It was applied to analyze platelet activation and aggregation responses in a prospective controlled study of patients with Finnish type of amyloidosis.
Javela, Kaija
core  

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A. Balogun   +4 more
wiley   +1 more source

Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway [PDF]

, 2003
Background: The regulation of platelet function by pharmacological agents that modulate platelet signaling haspharmacolo proven a successful approach to the prevention of thrombosis.
Cicmil, M, C. M. Williams, G. P. Hubbard, T. Sage, Stevens, J M; id_orcid, P. A. Jordan, J. M. Gibbins, M. Cicmil, Sage, T, Gibbins, J.M., Williams, C M, Gibbins, J M, Jordan, P A, Lovegrove, J A, Hubbard, G P, J. A. Lovegrove, J. M. Stevens, Stevens, J.M., Williams, C.M., Jordan, P.A., Lovegrove, J.A., Hubbard, G.P., Cicmil, M., Sage, T.   +23 more
core   +1 more source

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

MicroRNA-223-3p is a determinant of platelet procoagulant activity

Blood Advances
: MicroRNAs (miRNAs) are regulators of platelet function and may, thus, contribute to interindividual variability in platelet reactivity. MicroRNA-223-3p (miR-223-3p) is the most abundant of the platelet-derived miRNAs.
Julia Charlon-Gay, Séverine Nolli, Sylvie Dunoyer-Geindre, Paulina Ciepla, Jean-Luc Reny, Pierre Fontana   +5 more
doaj   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source